PMID- 35757196
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 15
DP  - 2022
TI  - Association Between Serum Asprosin and Diabetic Nephropathy in Patients with Type 
      2 Diabetes Mellitus in the Community: A Cross-Sectional Study.
PG  - 1877-1884
LID - 10.2147/DMSO.S361808 [doi]
AB  - OBJECTIVE: To explore the association between serum asprosin and diabetic 
      nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM) in the 
      community. METHODS: In this cross-sectional study, we retrospectively collected 
      the clinical data of T2DM patients from a community health service center in 
      southeastern Shanxi Province between November 2019 and July 2021. Logistic 
      regression analysis was used to calculate the odds ratio (OR) and the 95% 
      confidence interval (95% CI) of asprosin levels on the risk of DN. RESULTS: Among 
      498 T2DM patients included in this study, 221 had microalbuminuria, 105 had 
      massive albuminuria, and 172 did not have any signs of nephropathy. Serum 
      asprosin level was positively correlated with diastolic blood pressure, body mass 
      index, triglycerides, aspartate aminotransferase, alanine aminotransferase, 
      creatinine, ACR and albumin-to-creatinine ratio (all P < 0.05) and negatively 
      correlated with low-density lipoprotein cholesterol, high-density lipoprotein 
      cholesterol, fasting plasma glucose, HbA1c and estimated glomerular filtration 
      rate (all P < 0.05). After adjusting for covariates, increased asprosin was 
      associated with diabetic nephropathy (all OR = 2.560, 95% CI: 1.1592-4.116; P < 
      0.001). CONCLUSION: The risk of DN significantly increases with serum asprosin 
      levels, especially among female patients.
CI  - (c) 2022 Xu et al.
FAU - Xu, Linxin
AU  - Xu L
AD  - First Clinical Medical College, Shanxi Medical University, Taiyuan, People's 
      Republic of China.
AD  - Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
FAU - Cui, Junfang
AU  - Cui J
AD  - Department of Geratology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, 030001, People's Republic of China.
FAU - Li, Mina
AU  - Li M
AD  - Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
FAU - Wu, Qianqian
AU  - Wu Q
AD  - Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
FAU - Liu, Ming
AU  - Liu M
AD  - Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
FAU - Xu, Minggang
AU  - Xu M
AD  - Department of Endocrinology, Changzhi Second People's Hospital, Changzhi, 046000, 
      People's Republic of China.
FAU - Shi, Guoliang
AU  - Shi G
AD  - Department of Endocrinology, Changzhi Second People's Hospital, Changzhi, 046000, 
      People's Republic of China.
FAU - Yin, Jianhong
AU  - Yin J
AD  - Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
FAU - Yang, Jing
AU  - Yang J
AD  - First Clinical Medical College, Shanxi Medical University, Taiyuan, People's 
      Republic of China.
AD  - Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi 
      Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220618
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC9215350
OTO - NOTNLM
OT  - albuminuria
OT  - asprosin
OT  - community health services
OT  - creatinine
OT  - diabetic nephropathies
OT  - logistic models
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/06/28 06:00
MHDA- 2022/06/28 06:01
PMCR- 2022/06/18
CRDT- 2022/06/27 04:19
PHST- 2022/02/24 00:00 [received]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/06/27 04:19 [entrez]
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2022/06/28 06:01 [medline]
PHST- 2022/06/18 00:00 [pmc-release]
AID - 361808 [pii]
AID - 10.2147/DMSO.S361808 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2022 Jun 18;15:1877-1884. doi: 10.2147/DMSO.S361808. 
      eCollection 2022.